Synthesis, docking study, and in vitro anticancer evaluation of new flufenamic acid derivatives

• Main Authors: Ammar I. Al-Bayati, Ammar A. Razzak Mahmood, Zainab A. Al-Mazaydeh, Majdoleen S. Rammaha, Rheda I. Al-bayati, Fatima Alsoubani, Lubna H. Tahtamouni
• Format: Article
• Language: English
• Published: Pensoft Publishers 2021-05-01
• Series: Pharmacia
• Online Access: https://pharmacia.pensoft.net/article/66788/download/pdf/

Novel compounds (6–10) were synthesized and confirmed by spectroscopic analysis, including AT-IR, 1HNMR and CHNS. Their cytotoxic effect was evaluated by MTT assay against two cancer cell lines and two normal cell types. Compound 7 exhibited anticancer activity against MCF-7 breast cancer cell line (GI50 = 63.9 µg/ml, 148 µM), without any effect against A549 lung cancer cells, or the normal cells. Compound 7 caused cytotoxicity in MCF-7 breast cancer cells by apoptotic cell death, as suggested by fragmented nuclei after DAPI staining and agarose gel electrophoresis. In addition, treating MCF-7 cells with compound 7 resulted in an increase in the level of caspase 9 mRNA level, and its activation. Moreover, compound 7-treated MCF-7 cells showed enhanced cytochrome c release from the mitochondria to the cytosol, signifying an induction of the intrinsic apoptotic pathway. Finally, compound 7 exhibited epidermal growth factor receptor (EGFR) kinase inhibitory activity at (EC50 = 0.13 µM), which was matched by molecular docking studies that showed compound 7 might be an important EGFR kinase inhibitor.